March 18, 2020– A new report from a respected, independent congressional advisory panel sheds light on several of the key questions surrounding the 340B drug pricing program. In its March 2020 report to Congress, the Medicare Payment Advisory Commission (MedPAC) examined whether participation in the 340B program leads to higher drug spending for Medicare patients with five … [Read more...]
The 340B Proof of Concept: Better Patient Health
December 5, 2019– When policymakers assess whether programs they created are having positive impacts on people and communities, they ask for evidence that things are better than they were before the program took effect. When it comes to the 340B drug pricing program, that proof is in the improved health of patients. A new report by 340B Health has important information about … [Read more...]
Survey Raises Questions About Duplicate Discounts
Oct. 17, 2019– A newly released survey on the interplay of the 340B drug discount program and Medicaid has raised questions about what federal and state rules are in place to prevent duplicate discounts. The bottom line is that several such rules already exist in all 50 states to prevent pharmaceutical manufacturers from paying both a 340B discount and a Medicaid rebate on the … [Read more...]
340B May Curb High Drug Prices, New JAMA Study Finds
July 9, 2019– The 340B drug pricing program may discourage drug manufacturers from raising prices and instead may have the effect of reducing list prices for certain drugs. That’s according to a new study published in the Journal of the American Medical Association (JAMA). Study authors Sean Dickson of West Health and Ian Reynolds of the Pew Charitable Trusts evaluated the … [Read more...]
Focus on Rural Health Puts 340B in Spotlight
June 28, 2019– A pair of new reports demonstrate the precarious position of the nation’s rural health care system and underscore the need for the 340B drug pricing program to continue bolstering struggling safety-net hospitals caring for underserved rural communities. With more than 100 rural hospitals closing in the past decade, policymakers from across the political … [Read more...]
340B Helps Achieve Hepatitis C “Gold Standard” At Boston Medical Center
May 17, 2019– A recent study highlights how the 340B drug pricing program helps a safety-net hospital provide critical treatment to patients with Hepatitis C (HCV) and improve health outcomes. Published in the journal PLOS ONE, researchers at Boston Medical Center (BMC) found that the hospital’s 340B savings enabled them to operate a primary-care based multidisciplinary HCV … [Read more...]
Hits & Misses: 340B Commentary Gets Some Things Right But Misses on Others
November 28, 2018— In a recent commentary published in the Journal of the American Medical Association (JAMA), authors Peter Bach of Memorial Sloan Kettering Cancer Center and Rachel Sachs of Washington University in St. Louis call for an alternative financial mechanism for the 340B program, claiming the 340B program has resulted in market distortions and shifts in physician … [Read more...]